D. E. Shaw & Co. Inc. Invests $451,000 in LifeStance Health Group, Inc. (NASDAQ:LFST)

D. E. Shaw & Co. Inc. purchased a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 61,247 shares of the company's stock, valued at approximately $451,000.

Other institutional investors have also recently made changes to their positions in the company. Deutsche Bank AG raised its stake in LifeStance Health Group by 78.8% during the 4th quarter. Deutsche Bank AG now owns 120,163 shares of the company's stock worth $886,000 after buying an additional 52,970 shares during the period. Bank of America Corp DE increased its holdings in shares of LifeStance Health Group by 30.1% in the fourth quarter. Bank of America Corp DE now owns 396,662 shares of the company's stock worth $2,923,000 after buying an additional 91,796 shares during the period. BNP Paribas Financial Markets purchased a new position in LifeStance Health Group during the 4th quarter valued at about $876,000. Ameriprise Financial Inc. purchased a new position in LifeStance Health Group during the 4th quarter valued at about $87,000. Finally, Northern Trust Corp boosted its position in LifeStance Health Group by 11.7% during the 4th quarter. Northern Trust Corp now owns 1,591,776 shares of the company's stock valued at $11,731,000 after acquiring an additional 166,731 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

Wall Street Analysts Forecast Growth

LFST has been the topic of several research reports. William Blair reaffirmed an "outperform" rating on shares of LifeStance Health Group in a research report on Friday, February 28th. KeyCorp initiated coverage on LifeStance Health Group in a research report on Tuesday, April 8th. They set an "overweight" rating and a $9.00 price objective on the stock. Canaccord Genuity Group assumed coverage on LifeStance Health Group in a research report on Thursday, April 3rd. They set a "buy" rating and a $8.00 price objective on the stock. Finally, UBS Group raised LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price target on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $8.50.

LifeStance Health Group Stock Up 0.7%

LFST stock traded up $0.04 during midday trading on Friday, hitting $5.95. The company's stock had a trading volume of 1,492,548 shares, compared to its average volume of 1,591,819. The company has a market cap of $2.31 billion, a PE ratio of -22.88 and a beta of 1.30. LifeStance Health Group, Inc. has a 12 month low of $4.64 and a 12 month high of $8.61. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The firm's 50-day moving average is $6.32 and its 200-day moving average is $7.12.

Insider Buying and Selling

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the sale, the insider now directly owns 339,810 shares in the company, valued at approximately $2,344,689. The trade was a 5.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.20% of the stock is owned by corporate insiders.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.